A Cyclodiaryliodonium NOX Inhibitor for the Treatment of Pancreatic Cancer Via Enzyme-activatable Targeted Delivery by Sulfated Glycosaminoglycan Derivatives.
Sign Up to like & getrecommendations! Published in 2023 at "Advanced healthcare materials"
DOI: 10.1002/adhm.202203011
Abstract: Pancreatic cancer renders a principal cause of cancer mortalities with a dismal prognosis, lacking sufficiently safe and effective therapeutics. Here, we rationally design diversified cyclodiaryliodonium NADPH oxidase (NOX) inhibitors with tens of nanomolar optimal growth… read more here.
Keywords: pancreatic cancer; glycosaminoglycan derivatives; sulfated glycosaminoglycan; cancer ... See more keywords